Key facts
- SamanTree Medical’s last known valuation is $66.3M (Jul 2024).
- It has raised $50.4M; the latest was Debt - General ($23.4M) in Jan 2026.
- Notable investors include Venture Kick, b2venture, Venture (Switzerland), Brabantse Ontwikkelings Maatschappij, XAnge — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for SamanTree Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for SamanTree Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SamanTree Medical
Developer of medical imaging devices designed to improve cancer treatment care. The company's devices enable a global mapping of a lumpectomy for full margin control with histology-grade confidence before closing the incision, enabling clinicians to visualize cancerous cells on a surgical specimen during surgery.
- Sector
- Healthcare
- HQ
- Awans, Belgium
- Founded
- 2014
- Employees
- 48
- Website
- samantree.com/
- Ownership
- Privately Held (backing)
SamanTree Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SamanTree Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SamanTree Medical in its N-PORT filings yet. We sweep new filings monthly.